Lakefront Biotherapeutics (GLPGF) Consolidated Net Income (2014 - 2026)

Lakefront Biotherapeutics (GLPGF) has reported Consolidated Net Income for 13 consecutive years, with -$50.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Consolidated Net Income fell 128.49% year-over-year to -$50.2 million in Q2 2026; TTM through Jun 2026 was $330.1 billion, a 328.24% increase from a year earlier, with the FY2025 full-year figure at $320.5 billion, up 309.65% from the prior year.
• Consolidated Net Income was -$50.2 million for Q2 2026 at Lakefront Biotherapeutics, down from $17.1 million in the prior quarter.
• Over five years, Consolidated Net Income peaked at $330.8 billion in Q4 2025 and troughed at -$71.7 billion in Q4 2022.
• A 5-year average of $19.0 billion and a median of -$5.2 million in 2022 frame the typical range for Consolidated Net Income.
• Across the five-year window, Consolidated Net Income sank 5306830.92% in 2022 and surged 8954.39% in 2024, its largest moves.
• Over 5 years, Consolidated Net Income stood at -$71.7 billion in 2022, then jumped by 108.67% to $6.2 billion in 2023, then surged by 1141.91% to $77.2 billion in 2024, then jumped by 328.51% to $330.8 billion in 2025, then plunged by 100.02% to -$50.2 million in 2026.
• The last three Consolidated Net Income figures came in at -$50.2 million (Q2 2026), $17.1 million (Q1 2026), and $330.8 billion (Q4 2025), per Business Quant data.